ENG/中
老虎證券
行情
交易
收费
优惠与活动
帮助
TigerAI
专栏
关于
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
藥明合聯
57.100
0.000
手動刷新
成交量：
266.25萬
成交額：
1.53億
市值：
718.32億
市盈率：
45.02
高：
58.500
開：
57.800
低：
56.600
收：
57.100
52周最高：
85.500
52周最低：
24.700
股本：
12.58億
香港流通股本：
12.58億
量比：
0.97
換手率：
0.21%
股息：
- -
股息率：
- -
每股收益(LYR):
1.268
淨資產收益率：
17.05%
總資產收益率：
8.60%
市淨率：
5.91
市盈率(LYR):
45.02
市銷率:
10.67
資料載入中...
總覽
公司
新聞資訊
公告
【券商聚焦】交銀國際維持藥明合聯(02268)買入評級 指其今年有望迎來M端生產項目的大爆發
金吾财讯
·
昨天
《大行》里昂：藥明合聯(02268.HK)提高盈利可見性 目標價升至80.9元
阿斯达克财经
·
昨天
《大行》高盛微降藥明合聯(02268.HK)目標價至85.9元 今年指引符合預期
阿斯达克财经
·
昨天
中金：維持藥明合聯(02268)跑贏行業評級 目標價88.0港元
智通财经
·
昨天
從「賦能者」到「定義者」，CRDMO行業龍頭藥明合聯(02268)的持續進化與價值躍遷
智通财经
·
03/24
《大行》大摩予藥明合聯(02268.HK)評級「增持」 目標價86元
阿斯达克财经
·
03/24
觸底反彈！華寶基金港股通創新藥ETF、港股通醫療ETF攜手衝高3%！業績超預期，藥明合聯、藥明康德強勢領升
新浪基金
·
03/24
《大行》瑞銀下調藥明合聯(02268.HK)目標價至90.4元 產能擴張進度良好
阿斯达克财经
·
03/24
港股異動 | 創新藥概念股走高，藥明合聯升逾8%
老虎资讯综合
·
03/24
異動解讀 | 業績超預期！藥明合聯盤中大漲5.22%
异动解读
·
03/24
【券商聚焦】中信證券：GDF-15阻斷劑有望在未來獲批治療腫瘤惡病質
金吾财讯
·
03/24
藥明合聯2025年業績表現卓越，鞏固其在生物偶聯藥物CRDMO領域的全球領導地位
美股速递
·
03/23
藥明合聯(02268)2025年業績高增延續，「全球擴張+技術賦能」牢築行業龍頭地位
智通财经
·
03/23
藥明合聯(02268)2025年收益淨利雙增長 公司擁有人應占經調整純利約15.59億元 按年增長69.9%
智通财经网
·
03/23
【券商聚焦】交銀國際：CXO行情持續回暖 料板塊估值倍數合理
金吾财讯
·
03/23
港股異動 | 東曜藥業-B(01875)再升逾11% 年內股價已翻倍 藥明合聯收購要約正式生效
智通财经
·
03/20
【券商聚焦】中國銀河：「十五五」首次將生物醫藥列為國家新興支柱產業，持續發力研發創新
金吾财讯
·
03/20
港股異動 | 東曜藥業-B(01875)升逾9% 藥明合聯已取得公司60%股權有效接納 收購要約正式生效
智通财经
·
03/19
港股異動 | 東曜藥業-B(01875)午後升逾5% 藥明合聯收購條件到期未達成 要約期已延長
智通财经
·
03/17
港股生物醫藥概念股走高，藥明合聯漲近7%，榮昌生物升逾5%
老虎资讯综合
·
03/17
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02268/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"02268","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02268\",,,,,undefined,":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"藥明合聯","latestPrice":57.1,"timestamp":1774497900002,"preClose":57.1,"halted":0,"volume":2662500,"delay":0,"changeRate":0,"floatShares":1258000000,"shares":1258000000,"eps":1.2683414405235707,"marketStatus":"午間休市","change":0,"latestTime":"03-26 12:05:00","open":57.8,"high":58.5,"low":56.6,"amount":153324783,"amplitude":0.033275,"askPrice":57.2,"askSize":2500,"bidPrice":57.05,"bidSize":6500,"shortable":3,"etf":0,"ttmEps":1.266458178292452,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774501200000},"marketStatusCode":3,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":57.1,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"volumeRatio":0.969686,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02268\",,,,,undefined,":{"symbol":"02268","floatShares":1258000000,"roa":"8.60%","roe":"17.05%","lyrEps":1.268341,"volumeRatio":0.969686,"shares":1258000000,"dividePrice":0,"high":58.5,"amplitude":0.033275,"preClose":57.1,"low":56.6,"week52Low":24.7,"pbRate":"5.91","psRate":"10.67","week52High":85.5,"institutionHeld":0,"latestPrice":57.1,"committee":0.444444,"eps":1.2683414405235707,"divideRate":0,"volume":2662500,"delay":0,"ttmEps":1.266458178292452,"open":57.8,"prevYearClose":60.75,"prevWeekClose":52.95,"prevMonthClose":63.15,"prevQuarterClose":60.75,"fiveDayClose":54.2,"twentyDayClose":58.35,"sixtyDayClose":63.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02268\",params:#limit:5,,,undefined,":[{"date":"2026-04-29","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1777426200000,"name":null,"time":"","dateTimestamp":1777392000000,"actualEps":null},{"date":"2026-03-23","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-18","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-03-24","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-20","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724117400000,"name":null,"time":"","dateTimestamp":1724083200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02268\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02268\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":20,"updateTime":1770393600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02268\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02268","date":"2026-03-25","current":45.086368,"percent":0.148532,"low":30.568632,"twenty":44.877487,"median":58.288916,"eighty":71.661847,"high":153.052589,"avg":63.894504,"sd":26.158789,"marketCap":71831383455},"quantilePoints":[{"date":"2023-11-17","current":130.035431,"twenty":0.435785,"median":0.444801,"eighty":2.787891,"marketCap":32996488000},{"date":"2023-11-24","current":133.579843,"twenty":0.435785,"median":0.444801,"eighty":2.810425,"marketCap":34174934000},{"date":"2023-12-01","current":147.707211,"twenty":0.435785,"median":0.444801,"eighty":2.852893,"marketCap":37945961200},{"date":"2023-12-08","current":132.646927,"twenty":0.435785,"median":0.444801,"eighty":2.935117,"marketCap":33939244800},{"date":"2023-12-15","current":138.75437,"twenty":0.435785,"median":0.444801,"eighty":3.039251,"marketCap":35706913800},{"date":"2023-12-22","current":153.052589,"twenty":0.435785,"median":0.444801,"eighty":3.172504,"marketCap":39360096400},{"date":"2023-12-29","current":145.85951,"twenty":0.435785,"median":0.444801,"eighty":3.326638,"marketCap":37710272000},{"date":"2024-01-05","current":142.305018,"twenty":0.435785,"median":0.444801,"eighty":3.599996,"marketCap":36531826000},{"date":"2024-01-12","current":138.558869,"twenty":0.435785,"median":0.444801,"eighty":3.622774,"marketCap":35589069200},{"date":"2024-01-19","current":141.046625,"twenty":0.435785,"median":0.444801,"eighty":3.635946,"marketCap":36178292200},{"date":"2024-01-26","current":116.23004,"twenty":0.435785,"median":0.444801,"eighty":3.642902,"marketCap":29696839200},{"date":"2024-02-02","current":82.111439,"twenty":0.435785,"median":0.444801,"eighty":3.654128,"marketCap":20952769880},{"date":"2024-02-09","current":67.278987,"twenty":0.435825,"median":0.445043,"eighty":3.68657,"marketCap":17252449440},{"date":"2024-02-16","current":66.713097,"twenty":0.435798,"median":0.44487,"eighty":3.704054,"marketCap":17111035920},{"date":"2024-02-23","current":82.124312,"twenty":0.435798,"median":0.44487,"eighty":3.728385,"marketCap":20952769880},{"date":"2024-03-01","current":86.135235,"twenty":0.435812,"median":0.444939,"eighty":3.767614,"marketCap":21989802360},{"date":"2024-03-08","current":96.662972,"twenty":0.435812,"median":0.444939,"eighty":3.804363,"marketCap":24688443700},{"date":"2024-03-15","current":72.134287,"twenty":0.435812,"median":0.444939,"eighty":3.87411,"marketCap":18407326520},{"date":"2024-03-22","current":82.739174,"twenty":0.435812,"median":0.444939,"eighty":3.907844,"marketCap":21094183400},{"date":"2024-03-28","current":70.236298,"twenty":0.435812,"median":0.444939,"eighty":3.924107,"marketCap":21565561800},{"date":"2024-04-05","current":69.514463,"twenty":0.435772,"median":0.444721,"eighty":3.932321,"marketCap":21329872600},{"date":"2024-04-12","current":72.929575,"twenty":0.435785,"median":0.444801,"eighty":3.970214,"marketCap":22390474000},{"date":"2024-04-19","current":66.691535,"twenty":0.435785,"median":0.444801,"eighty":4.01279,"marketCap":20457822560},{"date":"2024-04-26","current":78.851628,"twenty":0.435812,"median":0.444939,"eighty":62.837086,"marketCap":24158143000},{"date":"2024-05-03","current":79.483533,"twenty":0.435812,"median":0.444939,"eighty":66.70016,"marketCap":24334909900},{"date":"2024-05-10","current":73.189732,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":22461180760},{"date":"2024-05-17","current":65.221538,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":19986444160},{"date":"2024-05-24","current":58.278715,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":17818103520},{"date":"2024-05-31","current":59.948577,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":18347300940},{"date":"2024-06-07","current":58.299117,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":17820354960},{"date":"2024-06-14","current":64.156468,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":19592809620},{"date":"2024-06-21","current":70.500097,"twenty":0.435812,"median":0.444939,"eighty":69.593748,"marketCap":21485024730},{"date":"2024-06-28","current":68.013259,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":20718557850},{"date":"2024-07-05","current":61.893714,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":18850294830},{"date":"2024-07-12","current":63.530585,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":19377240810},{"date":"2024-07-19","current":56.933019,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":17365265250},{"date":"2024-07-26","current":56.800526,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":17389217340},{"date":"2024-08-02","current":69.358964,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":21221551740},{"date":"2024-08-09","current":72.710245,"twenty":0.435812,"median":0.444939,"eighty":70.597189,"marketCap":22395204150},{"date":"2024-08-16","current":74.003491,"twenty":0.435812,"median":0.444939,"eighty":70.930659,"marketCap":22802389680},{"date":"2024-08-23","current":35.050376,"twenty":0.435812,"median":0.44524,"eighty":71.736965,"marketCap":22742129354},{"date":"2024-08-30","current":36.779427,"twenty":0.435812,"median":0.445278,"eighty":71.736965,"marketCap":24024219892},{"date":"2024-09-06","current":36.193339,"twenty":0.435812,"median":0.445278,"eighty":71.736965,"marketCap":23652773101},{"date":"2024-09-13","current":36.950123,"twenty":0.435812,"median":0.445611,"eighty":71.736965,"marketCap":24084130665},{"date":"2024-09-20","current":36.912594,"twenty":0.435798,"median":0.445732,"eighty":71.812082,"marketCap":24203952211},{"date":"2024-09-27","current":41.596291,"twenty":0.435798,"median":0.446064,"eighty":71.812082,"marketCap":27439133942},{"date":"2024-10-04","current":49.267448,"twenty":0.435798,"median":0.446181,"eighty":71.812082,"marketCap":32351817312},{"date":"2024-10-10","current":43.61955,"twenty":0.435812,"median":0.446472,"eighty":71.736965,"marketCap":28457617080},{"date":"2024-10-18","current":43.201999,"twenty":0.435798,"median":0.446694,"eighty":71.812082,"marketCap":28038241670},{"date":"2024-10-25","current":43.020102,"twenty":0.435798,"median":0.446852,"eighty":71.812082,"marketCap":27918420124},{"date":"2024-11-01","current":41.699543,"twenty":0.435798,"median":0.446999,"eighty":71.812082,"marketCap":27079669305},{"date":"2024-11-08","current":47.130705,"twenty":0.435852,"median":0.447279,"eighty":71.812082,"marketCap":30374761809},{"date":"2024-11-15","current":46.740281,"twenty":0.435852,"median":0.44753,"eighty":71.812082,"marketCap":29895475627},{"date":"2024-11-22","current":46.01742,"twenty":0.435852,"median":0.447785,"eighty":71.812082,"marketCap":29416189444},{"date":"2024-11-29","current":51.670123,"twenty":0.435852,"median":0.448371,"eighty":71.812082,"marketCap":33010835812},{"date":"2024-12-06","current":54.048034,"twenty":0.435852,"median":0.449445,"eighty":71.812082,"marketCap":34448694360},{"date":"2024-12-13","current":58.707371,"twenty":0.435852,"median":0.45138,"eighty":71.812082,"marketCap":37384322227},{"date":"2024-12-20","current":60.54506,"twenty":0.435852,"median":35.016583,"eighty":71.812082,"marketCap":38342894592},{"date":"2024-12-27","current":58.22519,"twenty":0.435852,"median":35.863906,"eighty":71.812082,"marketCap":36845125272},{"date":"2025-01-03","current":57.033249,"twenty":0.435852,"median":36.241161,"eighty":71.812082,"marketCap":36126195998},{"date":"2025-01-10","current":62.66188,"twenty":0.435852,"median":36.730689,"eighty":71.812082,"marketCap":39541110048},{"date":"2025-01-17","current":54.642634,"twenty":0.436361,"median":37.212991,"eighty":71.812082,"marketCap":34508605132},{"date":"2025-01-24","current":54.868028,"twenty":0.436606,"median":39.470644,"eighty":71.812082,"marketCap":34868069769},{"date":"2025-01-28","current":52.331181,"twenty":0.436643,"median":41.238065,"eighty":71.736965,"marketCap":33430211222},{"date":"2025-02-07","current":57.910706,"twenty":0.437089,"median":42.380717,"eighty":71.8872,"marketCap":36785214499},{"date":"2025-02-14","current":56.82028,"twenty":0.437089,"median":43.020102,"eighty":71.8872,"marketCap":36006374452},{"date":"2025-02-21","current":70.802488,"twenty":0.437089,"median":44.139364,"eighty":71.8872,"marketCap":45112811918},{"date":"2025-02-28","current":60.65941,"twenty":0.437089,"median":45.078416,"eighty":71.8872,"marketCap":38522626910},{"date":"2025-03-07","current":67.088057,"twenty":0.437583,"median":46.607669,"eighty":71.962317,"marketCap":42776291779},{"date":"2025-03-14","current":72.98104,"twenty":0.438098,"median":47.703312,"eighty":71.990989,"marketCap":46550670465},{"date":"2025-03-21","current":80.244903,"twenty":0.438098,"median":49.592986,"eighty":72.978175,"marketCap":51163799971},{"date":"2025-03-28","current":47.906694,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":54840613248},{"date":"2025-04-03","current":43.121995,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":49380552191},{"date":"2025-04-11","current":35.581021,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":40380451549},{"date":"2025-04-17","current":33.597127,"twenty":0.4381,"median":49.700845,"eighty":72.980467,"marketCap":38220427395},{"date":"2025-04-25","current":39.226609,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44663120338},{"date":"2025-05-02","current":40.829264,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":46586700218},{"date":"2025-05-09","current":38.818219,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44603008467},{"date":"2025-05-16","current":39.608151,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":45882474676},{"date":"2025-05-23","current":38.196121,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44379117053},{"date":"2025-05-30","current":41.172242,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":48047309655},{"date":"2025-06-06","current":42.866418,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":50152010328},{"date":"2025-06-13","current":46.041552,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":53888090995},{"date":"2025-06-20","current":41.240748,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":48174509918},{"date":"2025-06-27","current":40.971553,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":47994081042},{"date":"2025-07-04","current":46.000985,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":53888090995},{"date":"2025-07-11","current":47.288014,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":55339986740},{"date":"2025-07-18","current":50.925924,"twenty":0.438098,"median":50.569275,"eighty":72.98104,"marketCap":59550637905},{"date":"2025-07-25","current":57.660678,"twenty":0.438098,"median":51.683826,"eighty":72.98104,"marketCap":67671179437},{"date":"2025-08-01","current":57.245588,"twenty":0.438098,"median":52.545804,"eighty":72.98104,"marketCap":66768897045},{"date":"2025-08-08","current":57.73965,"twenty":0.43811,"median":53.257543,"eighty":72.98104,"marketCap":67513611340},{"date":"2025-08-15","current":64.222783,"twenty":31.309336,"median":54.856958,"eighty":72.98104,"marketCap":74981664691},{"date":"2025-08-22","current":48.130228,"twenty":34.419063,"median":54.952855,"eighty":72.98104,"marketCap":69501077151},{"date":"2025-08-29","current":46.988345,"twenty":35.581021,"median":54.952855,"eighty":72.98104,"marketCap":68176099944},{"date":"2025-09-05","current":54.370406,"twenty":36.186031,"median":55.113399,"eighty":72.98104,"marketCap":78808670381},{"date":"2025-09-12","current":57.034752,"twenty":36.596757,"median":55.50873,"eighty":72.98104,"marketCap":82819396110},{"date":"2025-09-19","current":59.571504,"twenty":36.911418,"median":56.000464,"eighty":72.98104,"marketCap":86441593568},{"date":"2025-09-26","current":63.204858,"twenty":37.279949,"median":56.495601,"eighty":72.98104,"marketCap":91475834102},{"date":"2025-10-03","current":72.025865,"twenty":37.670679,"median":56.699916,"eighty":72.980467,"marketCap":104491187679},{"date":"2025-10-10","current":60.90024,"twenty":38.189538,"median":56.97042,"eighty":72.98104,"marketCap":88221995708},{"date":"2025-10-17","current":57.936353,"twenty":38.732076,"median":57.121577,"eighty":72.98104,"marketCap":83863080123},{"date":"2025-10-24","current":59.821834,"twenty":39.226609,"median":57.526112,"eighty":72.98104,"marketCap":86623810506},{"date":"2025-10-31","current":63.630196,"twenty":39.774995,"median":57.92353,"eighty":72.98104,"marketCap":92275860553},{"date":"2025-11-07","current":58.827143,"twenty":40.354886,"median":58.251953,"eighty":72.98104,"marketCap":85257233036},{"date":"2025-11-14","current":59.953959,"twenty":41.172242,"median":58.455089,"eighty":72.98104,"marketCap":87136525462},{"date":"2025-11-21","current":57.356344,"twenty":41.596291,"median":58.554061,"eighty":72.98104,"marketCap":83322340564},{"date":"2025-11-28","current":56.291024,"twenty":42.018405,"median":58.564991,"eighty":72.98104,"marketCap":82071768197},{"date":"2025-12-05","current":57.95451,"twenty":42.42494,"median":58.564991,"eighty":72.98104,"marketCap":84642388897},{"date":"2025-12-12","current":56.819112,"twenty":42.866418,"median":58.860686,"eighty":72.98104,"marketCap":83137635317},{"date":"2025-12-19","current":59.902097,"twenty":43.024716,"median":58.930609,"eighty":72.98104,"marketCap":87855221510},{"date":"2025-12-24","current":53.787136,"twenty":43.211711,"median":58.930609,"eighty":72.98104,"marketCap":79132453088},{"date":"2026-01-02","current":52.131715,"twenty":43.875774,"median":58.940897,"eighty":73.022778,"marketCap":76998826280},{"date":"2026-01-09","current":60.097118,"twenty":44.079539,"median":58.920321,"eighty":72.979321,"marketCap":88984788643},{"date":"2026-01-16","current":59.868148,"twenty":44.329264,"median":59.011667,"eighty":72.978748,"marketCap":88933823858},{"date":"2026-01-23","current":58.064858,"twenty":44.542103,"median":59.011667,"eighty":72.978748,"marketCap":86172293688},{"date":"2026-01-30","current":52.991062,"twenty":44.673253,"median":58.945496,"eighty":72.939295,"marketCap":79001941874},{"date":"2026-02-06","current":53.067413,"twenty":44.72485,"median":58.907275,"eighty":72.769063,"marketCap":79316440050},{"date":"2026-02-13","current":54.647287,"twenty":44.764796,"median":58.707371,"eighty":72.713983,"marketCap":82146923636},{"date":"2026-02-20","current":54.893728,"twenty":44.79956,"median":58.576126,"eighty":72.595053,"marketCap":82398522177},{"date":"2026-02-27","current":52.350133,"twenty":44.938454,"median":58.531174,"eighty":72.112603,"marketCap":79442239320},{"date":"2026-03-06","current":49.767005,"twenty":45.116803,"median":58.469542,"eighty":72.01889,"marketCap":74913465582},{"date":"2026-03-13","current":45.00506,"twenty":45.116803,"median":58.377121,"eighty":71.985255,"marketCap":68057405340},{"date":"2026-03-20","current":44.215816,"twenty":45.114658,"median":58.350601,"eighty":71.8872,"marketCap":66610713729},{"date":"2026-03-25","current":42.832163,"twenty":44.877487,"median":58.288916,"eighty":71.661847,"marketCap":71831383455}],"updateTime":1774500217760},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02268\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622041039","title":"【券商聚焦】交銀國際維持藥明合聯(02268)買入評級 指其今年有望迎來M端生產項目的大爆發","url":"https://stock-news.laohu8.com/highlight/detail?id=2622041039","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622041039?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 13:20","pubTimestamp":1774416034,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，药明合联 2025年收入和经调整净利润分别同比增长46.7%/69.9%，符合此前业绩预告。毛利率大幅提升5.4ppts至36.0%，营业费用率大致平稳。展望2026年，公司预计考虑东曜并表后的收入增速将超40%；毛利率将保持稳定或仅有小幅波动。2026年，公司有望迎来M端生产项目的大爆发，预计2026-28年将合计有30个BLA递交，成为业绩新增长极。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977195","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"gpt_icon":0},{"id":"2622904986","title":"《大行》里昂：藥明合聯(02268.HK)提高盈利可見性 目標價升至80.9元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622904986","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622904986?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 11:50","pubTimestamp":1774410600,"startTime":"0","endTime":"0","summary":"该行认为这增强公司的盈利可见性，并缓解投资者对增长放缓的担忧。该行料药明合联今年至2028年收入增长分别为38%、31%及28%，纯利预测上调6%至13%，并将其目标价由70.7元上调至80.9元，重申“跑赢大市”评级。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231117104104222_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231117104104222_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512230/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512230/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"2622204533","title":"《大行》高盛微降藥明合聯(02268.HK)目標價至85.9元 今年指引符合預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2622204533","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622204533?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 10:32","pubTimestamp":1774405920,"startTime":"0","endTime":"0","summary":"高盛发表研究报告指，药明合联去年下半年业绩大致符合早前盈喜公告，收入按年升35.9%，净利润升26.4%至7.35亿元人民币(下同)。同期经调整净利润按年增长55%至8.11亿元，经调整净利润率由22%扩大至25%，受惠于营运杠杆及效率提升。该行将药明合联2026至2028年经调整净利润预测分别上调1.8%、上调1.4%及下调0.1%，以反映新加坡厂房投产，惟部分被大部分折旧与摊销成本于2027年入账所抵销；维持对其“买入”评级，目标价由87.1港元微降至85.9港元。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231117104108628_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231117104108628_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512184/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512184/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"2622504347","title":"中金：維持藥明合聯(02268)跑贏行業評級 目標價88.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622504347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622504347?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 10:29","pubTimestamp":1774405754,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑到东曜整合和新加坡投产费用上升，维持药明合联27年预测基本不变。维持跑赢行业评级和88.0港元目标价，对应26/27年47.0x/34.5x经调整P/E 。中金主要观点如下：2025年业绩符合该行预期2025年：公司实现营业收入59.44亿元，同比+46.7%;毛利率36%，+5.4ppt;经调整归母净利润15.59亿元，同比+69.9%。苏州基地：公司预计东曜药业收购将于26年3月底完成。2026年资本开支预计约31亿元，2026-2030年总投资约80亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268"],"gpt_icon":0},{"id":"2621550170","title":"從「賦能者」到「定義者」，CRDMO行業龍頭藥明合聯(02268)的持續進化與價值躍遷","url":"https://stock-news.laohu8.com/highlight/detail?id=2621550170","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621550170?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 14:27","pubTimestamp":1774333622,"startTime":"0","endTime":"0","summary":"一份亮眼的年度答卷，将全球生物偶联药CRDMO龙头药明合联推至聚光灯下。近日，药明合联与Earendil Labs达成潜在交易总额高达8.85亿美元的WuXiTecan-2技术授权合作。Part 2 项目漏斗的质量革命：从“赢得分子”到“锁定未来”财报显示，药明合联累计服务超1000个发现阶段项目，252个进入iCMC开发阶段，2025年有69个项目成功转化。根据财报显示，药明合联海外收入占比已达85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2621119032","title":"《大行》大摩予藥明合聯(02268.HK)評級「增持」 目標價86元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621119032","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621119032?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 10:55","pubTimestamp":1774320900,"startTime":"0","endTime":"0","summary":"大摩发表研究报告指，药明合联(02268.HK) 去年收入达59.44亿元人民币(下同)，按年升46.7%，毛利达21.39亿元，按年升72.5%，经调整净利润达15.59亿元，按年升69.9%，均略高于早前公布的盈喜预测。该行提及，药明合联重申2025至2030年收入年均复合增长率指引为30%至35%，高于弗若斯特沙利文对行业预测的25.6%水平。该行予其目标价86港元，评级“增持”。(ca/j)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-23 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231107083824175_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231107083824175_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511767/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511767/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"2621314220","title":"觸底反彈！華寶基金港股通創新藥ETF、港股通醫療ETF攜手衝高3%！業績超預期，藥明合聯、藥明康德強勢領升","url":"https://stock-news.laohu8.com/highlight/detail?id=2621314220","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621314220?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 10:05","pubTimestamp":1774317900,"startTime":"0","endTime":"0","summary":"3月24日，港股全线反弹，医药板块高弹领涨，创新药产业链急速修复，100%创新药研发标的——港股通创新药ETF、高CXO含量的港股通医疗ETF华宝双双高开，盘中一度涨超3%。昨日两只ETF均创下历史收盘新低。 个股方面，创新药龙头回暖，港股通创新药ETF权重股康方生物、信达生物、石药集团集体涨超2%。港股通医疗ETF华宝持仓药明系CXO龙头绩后大涨，药明合联涨超8%，药明康德涨超7%。 消息面，昨日晚间，药明系上市公司披露2025年业绩。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e9a6fe8ab3f76a85df162b075e8b47f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-24/doc-inhrzysz3556834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520880","SG9999014674.SGD","LU2045819591.USD","LU0052750758.USD","603259","LU2242644610.SGD","BK1141","LU0320764599.SGD","LU2125910500.SGD","02268","LU1934453819.USD","LU2488822045.USD","LU2328871848.SGD","BK0216","LU1997245094.SGD","02359","LU2495084118.USD","BK1576","BK1583","LU0708995583.HKD","LU1808992512.USD","LU1997245177.USD","LU1046422090.SGD","LU1979443071.USD","LU1969619763.USD","LU1997244956.HKD","LU0456842615.SGD"],"gpt_icon":0},{"id":"2621034874","title":"《大行》瑞銀下調藥明合聯(02268.HK)目標價至90.4元 產能擴張進度良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2621034874","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621034874?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:59","pubTimestamp":1774317540,"startTime":"0","endTime":"0","summary":"瑞银发表研究报告指，药明合联去年下半年业绩符合其初步数据，收入按年升35.9%至32.4亿元人民币(下同)，股东应占纯利7.35亿元，按年升26.4%。2025全年收入及经调整纯利分别按年升46.7%及69.9%。另外，公司的新加坡厂房将于2026年上半年投产，目前已收到10个后期临床制程方案请求，并已与海外客户签订多个项目。该行微调药明合联盈利预测，轻微上调2026及2027年开支预测，目标价由95.7港元下调至90.4港元，认为估值吸引，维持“买入”评级。沽空资料截至 2026-03-23 16:25。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231117104105862_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231117104105862_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511729/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511729/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"1143024702","title":"港股異動 | 創新藥概念股走高，藥明合聯升逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143024702","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143024702?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:42","pubTimestamp":1774316564,"startTime":"0","endTime":"0","summary":"3月24日，港股创新药概念股集体走高，$药明合联(02268)$涨超8%，$药明康德(02359)$涨超6%，$康诺亚-B(02162)$涨超4%，$药明生物(02269)$涨超3%，$石药集团(01093)$涨近3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e9a6fe8ab3f76a85df162b075e8b47f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014674.SGD","LU2488822045.USD","BK1574","BK4585","BK1141","BK1161","02268"],"gpt_icon":0},{"id":"1158899695","title":"異動解讀 | 業績超預期！藥明合聯盤中大漲5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158899695","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158899695?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:33","pubTimestamp":1774315994,"startTime":"0","endTime":"0","summary":"药明合联(02268.HK)今日盘中大涨5.22%，表现显著强于大市。消息面上，公司于前一交易日盘后公布了2025年度业绩报告。数据显示，公司全年收益达59.44亿元人民币，按年大幅增长46.7%；录得纯利14.8亿元人民币，同比增长38.4%。这份远超市场预期的亮眼成绩单，是推动股价今日走强的主要动力。强劲的业绩增长反映了公司主营业务良好的发展态势与盈利能力，增强了投资者对其未来发展的信心，从而吸引了资金的积极买入。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02268"],"gpt_icon":0},{"id":"2621052036","title":"【券商聚焦】中信證券：GDF-15阻斷劑有望在未來獲批治療腫瘤惡病質","url":"https://stock-news.laohu8.com/highlight/detail?id=2621052036","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621052036?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:01","pubTimestamp":1774314061,"startTime":"0","endTime":"0","summary":"目前GDF-15阻断剂行业处于临床开发阶段，尚无任何药物获批，多数临床管线处于早期阶段，进度最快的为辉瑞公司和CatalYm公司。鉴于Ponsegromab在II期临床试验中的优异结果以及Ponsegromab的II/III期临床试验设计，该机构认为其有望获批治疗肿瘤恶病质，成为GDF-15阻断剂上市后第一个适应症。后续如果Ponsegromab成功上市以及Visugromab读出积极数据，将催化GDF-15阻断剂市场快速增长。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977070","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK1593","LU0348783233.USD","09688","LU1303224171.USD","BK1574","LU1064131003.USD","BK1515","02228","LU0405327148.USD","LU2289578879.USD","02367","06160","BK1585","BK1191","LU1997245094.SGD","LU2328871848.SGD","BK1161","BK1147","LU1580142542.USD","BK1207","600030","IE00B543WZ88.USD","LU1781817850.SGD","03933","LU0640798160.USD","06030","01530","BK1564","LU1794554557.SGD","01099","SG9999014674.SGD","LU0348735423.USD","LU1655091616.SGD","LU0307460666.USD","02268","LU0405327494.USD","06821","BK0276","BK1141","09926","LU1328615791.USD","HK0000165453.HKD","LU0417516902.SGD","IE00BPRC5H50.USD","01789","LU1255011170.USD","BK0028","02196","LU0348825331.USD"],"gpt_icon":0},{"id":"1139697902","title":"藥明合聯2025年業績表現卓越，鞏固其在生物偶聯藥物CRDMO領域的全球領導地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1139697902","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139697902?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 21:17","pubTimestamp":1774271838,"startTime":"0","endTime":"0","summary":"药明合联在2025年取得了卓越的业绩表现，进一步巩固了其在生物偶联药物合同研究、开发与生产（CRDMO）领域的全球领导地位。公司展现出强劲的增长势头和业务韧性，持续获得全球合作伙伴的广泛认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1141","02268","SG9999014674.SGD"],"gpt_icon":0},{"id":"2621520705","title":"藥明合聯(02268)2025年業績高增延續，「全球擴張+技術賦能」牢築行業龍頭地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2621520705","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621520705?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 20:26","pubTimestamp":1774268789,"startTime":"0","endTime":"0","summary":"财务与业务数据亮眼，彰显龙头“确定性”药明合联2025年的财务表现，诠释了其在高速成长赛道中的龙头溢价。在自身有机增长动能充沛之际，药明合联把握战略契机，于2026年初启动对东曜药业的控股收购，这并非简单的规模叠加，而是在“有机扩展+战略并购”双轮驱动下，进一步深化全球领导地位的战略棋局。收购预计在2026年3月底完成，随后进入全面整合阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f8405c8fed8428607b7c9694048343b7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"药明合联(02268)2025年业绩高增延续，“全球扩张+技术赋能”牢筑行业龙头地位","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268","LU2488822045.USD","SG9999014674.SGD","BK1141"],"gpt_icon":1},{"id":"2621703218","title":"藥明合聯(02268)2025年收益淨利雙增長 公司擁有人應占經調整純利約15.59億元 按年增長69.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703218","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703218?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 20:15","pubTimestamp":1774268148,"startTime":"0","endTime":"0","summary":"药明合联(02268)公布2025年业绩，收益约59.44亿元，同比增长46.7%;毛利约21.39亿元，同比增长72.5%;公司拥有人应占经调整纯利约15.59亿元，同比增长69.9%;纯利同比增长38.4%至14.8亿元。集团未完成订单总量亦由2024年12月31日的9.91亿美元增长50.3%至2025年12月31日的14.89亿美元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2488822045.USD","BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交銀國際：CXO行情持續回暖 料板塊估值倍數合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621095723?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU2476274720.SGD","02268","BK1583","09688","BK1617","BK1585","LU0634319403.HKD","LU0417516738.SGD","02196","BK1500","LU0307460666.USD","LU0348767384.USD","LU2488822045.USD","LU2399975544.HKD","BK1593","BK1141","02228","BK1207","LU1115378108.SGD","BK1191","LU0417516571.SGD","02367","LU2476274308.USD","03933","LU1770034418.SGD","03329","01789","IE00B543WZ88.USD","BK1574","BK1161","LU2778985437.USD","BK1588","BK1197","LU0348766576.USD","LU1719994722.HKD","06821","09926","LU1794554557.SGD","01099","LU0348784397.USD","LU0348827113.USD","LU0348735423.USD","LU0540923850.HKD","LU0417516902.SGD","LU1303224171.USD","LU2328871848.SGD","CXO","06160","01530"],"gpt_icon":0},{"id":"2620205448","title":"港股異動 | 東曜藥業-B(01875)再升逾11% 年內股價已翻倍 藥明合聯收購要約正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620205448","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620205448?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 10:00","pubTimestamp":1773972047,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B再涨超11%，年内股价已实现翻倍，截至发稿，涨9.94%，报5.75港元，成交额2108.74万港元。消息面上，药明合联宣布，药明合联对东曜药业的现金要约收购已取得东曜药业60%股权之有效接纳，股份要约已正式生效。根据香港联交所披露的文件，3月17日，WuXi XDC Cayman Inc.以每股均价4.0港元场外增持东曜药业4.64亿股普通股股份，价值约18.55亿港元。增持后，其最新持股数目为4.64亿股股份，好仓比例由0.00%升至60.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"716700f540e2f30ce9084471cdfe18ec","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1574","SG9999014674.SGD","BK1141","BK1161","02268","LU2488822045.USD","BK4585","BK4588","01875"],"gpt_icon":0},{"id":"2620203185","title":"【券商聚焦】中國銀河：「十五五」首次將生物醫藥列為國家新興支柱產業，持續發力研發創新","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203185","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620203185?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 09:23","pubTimestamp":1773969824,"startTime":"0","endTime":"0","summary":"“十四五”规划重点关注医药创新产品产业化、医药产业化技术攻关、疫苗和短缺药品供应保障、产品质量升级、医药工业绿色低碳等五大工程，成效斐然，中国创新药获批上市数量由2015年的11款提升至2024年的92款，2024年共有22款国产化药和17款国产生物药获批上市，国产创新药占比提升至42%。“十五五”规划提出健全医疗、医保、医药协同发展和治理机制，生物医药产业首次被列为国家“新兴支柱产业”，战略定位进一步提升。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","LU0348766576.USD","BK4588","LU2778985437.USD","LU2045819591.USD","02359","161726","XBI","HK0000306701.USD","LU2328871848.SGD","02696","601881","HK0000320223.HKD","LU2476274308.USD","06881","LU0348825331.USD","BK1141","BK1588","HK0000306685.HKD","02268","09995","LU2476274720.SGD","BK4585","LU0561508036.HKD","LU0708995583.HKD","09926","LU0348767384.USD","LU1720050803.USD","LU0417516571.SGD","LU1770034418.SGD","06160","LU0348735423.USD","399441","LU2125910500.SGD","LU2242644610.SGD","SG9999014674.SGD","LU0052750758.USD","BK1147","BK1161","BK1564","LU0196878994.USD","IE00B543WZ88.USD","LU0540923850.HKD","06990","BK4581","LU0588546209.SGD","02162","LU1969619763.USD","BK0276"],"gpt_icon":0},{"id":"2620292008","title":"港股異動 | 東曜藥業-B(01875)升逾9% 藥明合聯已取得公司60%股權有效接納 收購要約正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292008","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292008?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 09:57","pubTimestamp":1773885457,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B涨超9%，截至发稿，涨8.02%，报4.85港元，成交额1989.09万港元。消息面上，3月18日，药明合联宣布，公司已成功获得东曜药业60%股权之有效接纳，本次收购要约已正式生效。据药明合联介绍，本次收购要约的最后可接纳截止日期为2026年3月31日下午4时，东曜药业股东将在剩余的时间里决策是否接纳本次要约。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1161","BK1141","VXUS","BK1574","LU2488822045.USD","BK4585","SG9999014674.SGD","02268","BK4588"],"gpt_icon":0},{"id":"2620449190","title":"港股異動 | 東曜藥業-B(01875)午後升逾5% 藥明合聯收購條件到期未達成 要約期已延長","url":"https://stock-news.laohu8.com/highlight/detail?id=2620449190","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620449190?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 15:23","pubTimestamp":1773732198,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B(01875)午后涨超5%，截至发稿，涨4.04%，报43.8港元，成交额815.65万港元。消息面上，今年1月，东曜药业获药明合联溢价约99%提现金要约。据悉，本次收购成功的关键在于药明合联能否在截止日期前获得至少60%的东曜药业投票权。药明合联此前已经锁定了持有42.16%股份的五大主要股东的“不可撤销承诺”。3月13日，公司公告称，由于接纳条件于首个截止日期未获达成，要约人把首个截止日期延长至2026年3月27日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02268","SG9999014674.SGD","VXUS","BK4588","01875","BK1141","BK4585","LU2488822045.USD"],"gpt_icon":0},{"id":"1150046369","title":"港股生物醫藥概念股走高，藥明合聯漲近7%，榮昌生物升逾5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150046369","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150046369?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 10:28","pubTimestamp":1773714505,"startTime":"0","endTime":"0","summary":"3月17日，$生物(000504)$医药概念股走高，$药明合联(02268)$涨近7%，$荣昌生物(09995)$涨超5%，$君实生物(01877)$、$诺诚健华(09969)$、$药明康德(02359)$等个股跟涨","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5f115a7e903cc298acc05fac997c6569","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1141","SG9999014674.SGD","BK1583","LU1064131003.USD","BK1161","02268","LU2328871848.SGD","BK4581","LU2488822045.USD","BK1574","09995","LU1064130708.USD","BK4585","LU2148510915.USD","LU1969619763.USD","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}